Review



human gfap  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems human gfap
    Human Gfap, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gfap/product/R&D Systems
    Average 93 stars, based on 15 article reviews
    human gfap - by Bioz Stars, 2026-06
    93/100 stars

    Images



    Similar Products

    human gfap duoset elisa  (Bio-Techne corporation)
    94
    Bio-Techne corporation human gfap duoset elisa
    Human Gfap Duoset Elisa, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gfap duoset elisa/product/Bio-Techne corporation
    Average 94 stars, based on 1 article reviews
    human gfap duoset elisa - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    human gfap  (R&D Systems)
    93
    R&D Systems human gfap
    Human Gfap, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gfap/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human gfap - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    human gfap duoset elisa  (R&D Systems)
    93
    R&D Systems human gfap duoset elisa
    Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; <t>GFAP,</t> glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.
    Human Gfap Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gfap duoset elisa/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human gfap duoset elisa - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    r d systems elisa kit  (R&D Systems)
    93
    R&D Systems r d systems elisa kit
    Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; <t>GFAP,</t> glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.
    R D Systems Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r d systems elisa kit/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    r d systems elisa kit - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    elisa kit  (R&D Systems)
    94
    R&D Systems elisa kit
    Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; <t>GFAP,</t> glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.
    Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa kit/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    elisa kit - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    elisa kit nº dy259405  (R&D Systems)
    94
    R&D Systems elisa kit nº dy259405
    Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; <t>GFAP,</t> glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.
    Elisa Kit Nº Dy259405, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa kit nº dy259405/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    elisa kit nº dy259405 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; GFAP, glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.

    Journal: Annals of Clinical and Translational Neurology

    Article Title: Clinical characteristics of double negative atypical inflammatory demyelinating disease: A prospective study

    doi: 10.1002/acn3.52191

    Figure Lengend Snippet: Inclusion procedure of double negative atypical IDD, MS, AQP4‐IgG + NMOSD, and MOGAD. Of the 298 patients initially enrolled, 98 double‐negative atypical IDD, 73 AQP4‐IgG‐positive NMOSD, 23 MOGAD, and 63 MS patients were finally included in the analysis after rigorous screening. AQP4, aquaporin‐4; GFAP, glial fibrillary acidic protein; IDD, inflammatory demyelinating diseases; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligodendrocyte glycoprotein antibody associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.

    Article Snippet: Serum GFAP of double negative atypical IDD patients was quantified using commercial Human GFAP DuoSet ELISA (R&D Systems Minneapolis, MN, USA) by an independent investigator who was blinded to the result of TBA.

    Techniques:

    The specificity and sensitivity of the TBA using a rat brain indirect immunofluorescence. (A) The TBA results of the specimens that positive for AQP4‐IgG or GFAP‐IgG determined by CBA. (B) The TBA results of the specimens tested negative for AQP4‐IgG, GFAP‐IgG, and MOG‐IgG determined by CBA. AQP4, aquaporin‐4; CNS, central nervous system; IDD, inflammatory demyelinating diseases; MOGAD, myelin oligodendrocyte glycoprotein antibody‐associated disease; MS, multiple sclerosis; NIE, noninflammatory encephalopathy; NIM, noninflammatory myelopathy; NIPN, noninflammatory peripheral neuropathy; NMOSD, neuromyelitis optica spectrum disorders.

    Journal: Annals of Clinical and Translational Neurology

    Article Title: Clinical characteristics of double negative atypical inflammatory demyelinating disease: A prospective study

    doi: 10.1002/acn3.52191

    Figure Lengend Snippet: The specificity and sensitivity of the TBA using a rat brain indirect immunofluorescence. (A) The TBA results of the specimens that positive for AQP4‐IgG or GFAP‐IgG determined by CBA. (B) The TBA results of the specimens tested negative for AQP4‐IgG, GFAP‐IgG, and MOG‐IgG determined by CBA. AQP4, aquaporin‐4; CNS, central nervous system; IDD, inflammatory demyelinating diseases; MOGAD, myelin oligodendrocyte glycoprotein antibody‐associated disease; MS, multiple sclerosis; NIE, noninflammatory encephalopathy; NIM, noninflammatory myelopathy; NIPN, noninflammatory peripheral neuropathy; NMOSD, neuromyelitis optica spectrum disorders.

    Article Snippet: Serum GFAP of double negative atypical IDD patients was quantified using commercial Human GFAP DuoSet ELISA (R&D Systems Minneapolis, MN, USA) by an independent investigator who was blinded to the result of TBA.

    Techniques: Immunofluorescence

    TBA immunofluorescence patterns of autoantibodies against astrocytes, neurons, or oligodendrocyte in double negative atypical IDD patients. (A) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to astrocytes at rat cerebral cortex (green), similar to commercial AQP4‐IgG (red). (B) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to astrocytes at rat cerebral cortex (green), similar to commercial GFAP‐IgG (red). (C) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to neurons at rat cerebral cortex (green), similar to commercial NeuN‐IgG (red). (D) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to oligodendrocytes at rat cerebellum (green), similar to commercial MOG‐IgG (red). (E) Seronegative immunofluorescence pattern. Nuclei were counterstained with 4′,6‐diamidino‐2‐phenylindole (DAPI) (blue). Scale bars: 100 μm. AQP4, aquaporin‐4; GFAP, glial fibrillary acidic protein; MOG, myelin oligodendrocyte glycoprotein; NeuN, neuronal nucleus.

    Journal: Annals of Clinical and Translational Neurology

    Article Title: Clinical characteristics of double negative atypical inflammatory demyelinating disease: A prospective study

    doi: 10.1002/acn3.52191

    Figure Lengend Snippet: TBA immunofluorescence patterns of autoantibodies against astrocytes, neurons, or oligodendrocyte in double negative atypical IDD patients. (A) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to astrocytes at rat cerebral cortex (green), similar to commercial AQP4‐IgG (red). (B) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to astrocytes at rat cerebral cortex (green), similar to commercial GFAP‐IgG (red). (C) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to neurons at rat cerebral cortex (green), similar to commercial NeuN‐IgG (red). (D) An immunofluorescence pattern of antibodies from patients with double negative atypical IDD binding to oligodendrocytes at rat cerebellum (green), similar to commercial MOG‐IgG (red). (E) Seronegative immunofluorescence pattern. Nuclei were counterstained with 4′,6‐diamidino‐2‐phenylindole (DAPI) (blue). Scale bars: 100 μm. AQP4, aquaporin‐4; GFAP, glial fibrillary acidic protein; MOG, myelin oligodendrocyte glycoprotein; NeuN, neuronal nucleus.

    Article Snippet: Serum GFAP of double negative atypical IDD patients was quantified using commercial Human GFAP DuoSet ELISA (R&D Systems Minneapolis, MN, USA) by an independent investigator who was blinded to the result of TBA.

    Techniques: Immunofluorescence, Binding Assay